The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On March 16, Cingulate Inc received approval from the US Patent and Trademark Office (USPTO) for a key patent application related to its ADHD treatment. The patent protects the proprietary technology behind CTx-1301, the company's lead ADHD drug candidate. Following this announcement, Cingulate Inc (CING) shares surged in Monday morning trading.